Inhibikase Grants Stock Options to New Employees Under Nasdaq Inducement Plan
Inhibikase Therapeutics grants 685,718 stock options at $1.68/share to five new hires under Nasdaq inducement plan with ten-year terms.
IKTvesting schedulepharmaceutical company